PMID- 32761455
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230214
IS  - 0303-4240 (Print)
IS  - 0303-4240 (Linking)
VI  - 185
DP  - 2023
TI  - Patterns of Ciliation and Ciliary Signaling in Cancer.
PG  - 87-105
LID - 10.1007/112_2020_36 [doi]
AB  - Among the factors that have been strongly implicated in regulating cancerous 
      transformation, the primary monocilium (cilium) has gained increasing attention. 
      The cilium is a small organelle extending from the plasma membrane, which 
      provides a localized hub for concentration of transmembrane receptors. These 
      receptors transmit signals from soluble factors (including Sonic hedgehog (SHH), 
      platelet-derived growth factor (PDGF-AA), WNT, TGFbeta, NOTCH, and others) that 
      regulate cell growth, as well as mechanosensory cues provided by flow or 
      extracellular matrix. Ciliation is regulated by cell cycle, with most cells that 
      are in G0 (quiescent) or early G1 ciliation and cilia typically absent in G2/M 
      cells. Notably, while most cells organized in solid tissues are ciliated, 
      cancerous transformation induces significant changes in ciliation. Most cancer 
      cells lose cilia; medulloblastomas and basal cell carcinomas, dependent on an 
      active SHH pathway, rely on ciliary maintenance. Changes in cancer cell ciliation 
      are driven by core oncogenic pathways (EGFR, KRAS, AURKA, PI3K), and importantly 
      ciliation status regulates functionality of those pathways. Ciliation is both 
      influenced by targeted cancer therapies and linked to therapeutic resistance; 
      recent studies suggest ciliation may also influence cancer cell metabolism and 
      stem cell identity. We review recent studies defining the relationship between 
      cilia and cancer.
CI  - (c) 2020. The Author(s), under exclusive license to Springer Nature Switzerland AG.
FAU - Kiseleva, Anna A
AU  - Kiseleva AA
AD  - Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 
      USA.
FAU - Nikonova, Anna S
AU  - Nikonova AS
AD  - Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 
      USA.
FAU - Golemis, Erica A
AU  - Golemis EA
AD  - Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, 
      USA. Erica.golemis@fccc.edu.
LA  - eng
GR  - P30 CA006927/CA/NCI NIH HHS/United States
GR  - R01 DK108195/DK/NIDDK NIH HHS/United States
GR  - R21 CA228187/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Rev Physiol Biochem Pharmacol
JT  - Reviews of physiology, biochemistry and pharmacology
JID - 0434624
RN  - 0 (Hedgehog Proteins)
SB  - IM
MH  - Humans
MH  - *Hedgehog Proteins/metabolism
MH  - Signal Transduction/physiology
MH  - Cell Cycle/physiology
MH  - Cell Proliferation
MH  - *Neoplasms/metabolism
MH  - Cilia/metabolism
PMC - PMC9916338
MID - NIHMS1869766
OTO - NOTNLM
OT  - Aurora-A
OT  - Cilium
OT  - Extracellular vesicle
OT  - NEDD9
OT  - Stroma
OT  - Targeted therapy
EDAT- 2020/08/08 06:00
MHDA- 2023/02/01 06:00
PMCR- 2023/02/10
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2023/02/01 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2023/02/10 00:00 [pmc-release]
AID - 10.1007/112_2020_36 [doi]
PST - ppublish
SO  - Rev Physiol Biochem Pharmacol. 2023;185:87-105. doi: 10.1007/112_2020_36.